THE Bank of England’s actions to tame inflation have just begun to impact households and the effects will be felt to a greater extent next year, a policymaker has said.
Last month, the central bank froze interest rates at 5.25 per cent following a surprise slowdown in inflation.
Its decision to hold borrowing costs at the highest level in more than 15 years followed 14 straight hikes after global inflation soared to the highest levels in decades.
Britain’s economy expanded in August by 0.2 per cent up from a contraction of 0.6 per cent in July, Office for National Statistics data showed.
The BoE’s Monetary Policy Committee member Swati Dhingra said interest rates were expected to remain high for some time and this would affect millions of households - mostly young and poor - next year.
“We think only about 20 per cent or 25 per cent of the impact of the interest rate hikes have been fed through to the economy,” she told the BBC.
“I think that there’s also this worry that that might mean that we’re going to have to pay a higher cost than we should be paying.”
Britain’s economy “has already flatlined”, according to the associate professor at the London School of Economics, who obtained her master’s degree from the University of Delhi and her PhD from the University of Wisconsin-Madison.
Dhingra, who was appointed to the central bank’s interest rate setting committee in August last year, said high food and energy costs disproportionately affected low-income groups, while the increase in mortgage costs and rents hit young people.
She said the GDP growth in August was too small to avert a recession.
“When you’re growing as slowly as we’re growing now, the chances of recession or not recession are going to be pretty equally balanced. So we should be prepared for that … it’s not going to be great times ahead,” Dhingra said.
Earlier this week, the central bank noted that the outlook for global economic growth remained “weak in the near term”.
It warned that interest rates “may need to rise further" if inflation remained stubborn.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.